Cosmetic healing blend: TB-500 + BPC-157 + GHK-Cu
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 3.5 mg | Daily | 10 units daily (0.1 mL) Delivers per dose: TB-4: 0.5 mg BPC-157: 0.5 mg GHK-Cu: 2.5 mg |
| Intermediate | 5 mg | Daily | 20 units daily (0.2 mL) Split if needed (10 AM / 10 PM) Delivers per day: TB-4: 1.0 mg BPC-157: 1.0 mg GHK-Cu: 5 mg |
| Advanced | 7 mg | Daily | 20 units daily (0.2 mL) Split if needed (10 AM / 10 PM) Delivers per day: TB-4: 1.0 mg BPC-157: 1.0 mg GHK-Cu: 5 mg |
| Maximum | 10 mg | Daily | — |
Blend Dosing Approach
GLOW is formulated as a **fixed-ratio blend** with predetermined concentrations of TB-500 (10mg), BPC-157 (10mg), and GHK-Cu (50mg) that have been optimized based on individual peptide research and their complementary mechanisms. This **pre-combined format** eliminates the complexity of managing multiple vials and injection schedules, ensuring consistent ratios with each dose. Since the peptides are already mixed, dosing becomes **volume-based** rather than requiring separate calculations for each component. The convenience of a single injection may also improve research compliance and reduce administration errors. Typical research protocols suggest subcutaneous administration, though the specific timing and frequency should be based on individual research goals and the relatively short half-lives of these peptides, which generally favor more frequent dosing schedules.
Per-Component Breakdown
Synergy Rationale
The GLOW blend combines three peptides that address different yet complementary aspects of tissue repair and regeneration. **TB-500** provides the foundational healing mechanism through **actin modulation** and enhanced cellular migration, ensuring that repair cells can efficiently reach injury sites. **BPC-157** contributes powerful **angiogenic support** and **anti-inflammatory modulation**, creating optimal healing environments with improved blood flow and nutrient delivery. **GHK-Cu** completes the formula by driving **collagen synthesis** and **gene expression reprogramming** that supports long-term tissue quality and appearance. This combination addresses the full healing cascade: TB-500 initiates cellular movement and wound response, BPC-157 establishes vascular support and reduces harmful inflammation, while GHK-Cu ensures proper extracellular matrix formation and tissue remodeling. The scientific rationale centers on targeting multiple rate-limiting steps in healing simultaneously rather than relying on a single mechanism, potentially creating **synergistic effects** where the combined impact exceeds individual peptide benefits.
Combined Mechanism
The GLOW peptides create a coordinated healing response through overlapping **angiogenic**, **anti-inflammatory**, and **tissue remodeling pathways**. All three peptides influence **VEGF signaling** - TB-500 and BPC-157 directly upregulate VEGF expression while GHK-Cu enhances VEGF gene transcription, potentially creating amplified angiogenic responses. Their **anti-inflammatory effects** work through complementary mechanisms: TB-500 modulates cytokine expression during cellular migration, BPC-157 reduces pro-inflammatory mediators like **TNF-α** and **IL-6**, while GHK-Cu downregulates inflammatory genes at the transcriptional level. The **extracellular matrix remodeling** represents another convergent pathway - TB-500 influences collagen organization to reduce scarring, BPC-157 enhances fibroblast activity and collagen synthesis, and GHK-Cu directly upregulates genes encoding **collagen types I and III** and elastin. This multi-level coordination may result in faster initial healing response (TB-500), sustained tissue repair with optimal vascularization (BPC-157), and superior final tissue quality with enhanced structural proteins (GHK-Cu). The temporal profile suggests immediate anti-inflammatory and cellular migration effects, followed by sustained angiogenesis and matrix remodeling over weeks.
Research Context
While extensive research exists for each individual peptide, **direct studies on this specific three-peptide combination are limited** in peer-reviewed literature. However, research on similar **multi-peptide healing formulations** suggests that combining peptides with complementary mechanisms can enhance overall therapeutic outcomes. The scientific rationale for this combination is supported by studies showing that **multi-target approaches** to tissue repair often outperform single-agent treatments. Each peptide in GLOW has demonstrated efficacy in overlapping applications - wound healing, angiogenesis, and tissue regeneration - suggesting potential for **additive or synergistic effects**. Current understanding is primarily based on extrapolating from individual peptide mechanisms and general principles of combination therapy. This represents an area where **additional research is needed** to definitively establish the benefits and optimal ratios of this specific combination, though the theoretical framework and individual component efficacy provide strong scientific foundation.
Research Use Only: All compounds discussed on this page are intended for laboratory research purposes only. Not for human consumption. All research should be conducted in compliance with institutional guidelines and applicable regulations. Consult qualified healthcare professionals before making any decisions regarding compound research or use.
GLOW
Quick Reference
- Default Dose
- 3.5 mg
- Frequency
- Daily
- Timing
- AM
- Dilution
- 2 mL
For Practitioners
Interested in offering research-grade compounds through your practice? Learn about our affiliate program for qualified practitioners.
Find a ProviderPractitioner Information